Sign in

Sven A. Wehrwein

Director at AtriCure
Board

About Sven A. Wehrwein

Independent director since November 2016, age 73, with more than three decades across accounting and finance as a CPA (inactive), investment banker, CFO, and audit committee/board chair; he holds a B.S. in Business from Loyola University Chicago and an M.S. in Management from MIT Sloan . He currently serves as ATRC’s Audit Committee Chair and is designated an SEC “audit committee financial expert,” reflecting deep governance, M&A, auditing and financial planning expertise .

Past Roles

OrganizationRoleNotes
Cogentix Medical, Inc.Director (prior)Medical device/high-growth company board service
Compellent Technologies, Inc.Director (prior)High-growth tech company board service
Synovis Life Technologies, Inc.Director (prior)Medical device company board service
Vital ImagesDirector (prior)Imaging/health tech board service
Nonin Medical, Inc.Director (prior)Medical device company board service
CFO roles (unspecified companies)CFO (prior)Prior executive finance leadership; firms not disclosed in proxy

External Roles

OrganizationRoleCommittees/Impact
Proto Labs, Inc.Director (current)Public company board; specific committee roles not disclosed in ATRC proxy
SPS Commerce, Inc.Director (current)Public company board; specific committee roles not disclosed in ATRC proxy

Board Governance

CommitteeRoleMeetings (2023)Meetings (2024)
Audit CommitteeChair5 6
Compliance, Quality & Risk CommitteeMember4 5
  • Independence: Board has affirmatively determined he is independent; all committees (except the CEO on Board) meet NASDAQ independence requirements .
  • Financial Expertise: Designated “audit committee financial expert” .
  • Attendance and engagement: All directors attended ≥75% of their Board/committee meetings and attended the annual meeting in 2022 and 2023 .
  • Audit Committee report signatory: Listed as Audit Committee Chair in committee report sections .

Fixed Compensation

YearFees Earned or Paid in Cash ($)Stock Awards ($)Total ($)
202377,500 149,965 227,465
202477,500 174,996 252,496

Director retainer structure (non-employee directors):

  • Annual cash retainer: $50,000; Board Chair add’l $50,000 (not applicable to Wehrwein) .
  • Annual stock retainer: $175,000 (increased beginning 2024; 2023 retainer was $150,000) .
  • Committee fees: Audit Chair $20,000; Audit membership $10,000; Compensation Chair $15,000 (membership $7,500); Compliance Chair $15,000 (membership $7,500); Nominating Chair $10,000 (membership $5,000); Strategy Chair $10,000 (membership $7,500) .

Performance Compensation

Element20232024
Annual equity vehicleRestricted stock (time-vested; 1-year vest) Restricted stock (time-vested; earlier of one-year anniversary or next annual meeting ≥50 weeks)
Initial appointment grant~$175,000 RS; vests over 3 years (in lieu of annual) ~$175,000 RS; vests over 3 years (in lieu of annual)
Stock options granted to directorsNone None
  • No performance-based metrics (e.g., TSR, revenue, EBITDA) are disclosed for director compensation; equity awards are time-based restricted stock only .

Other Directorships & Interlocks

CompanyTypePotential Interlock/Conflict Disclosure
Proto Labs, Inc.Public companyNo ATRC-related party transactions disclosed; Audit Committee reviews potential related party transactions .
SPS Commerce, Inc.Public companyNo ATRC-related party transactions disclosed; Audit Committee oversight policy in place .
  • Compensation Committee Interlocks: None reported; no cross-compensation committee interlocks for ATRC .

Expertise & Qualifications

  • CPA (inactive), investment banker, CFO experience; audit and governance chair experience .
  • SEC-designated audit committee financial expert .
  • Skills highlighted by Board: finance & SOX compliance, corporate governance, M&A, risk management; broad public board service .

Equity Ownership

HolderSharesOptions Exercisable within 60 DaysPercent of Class
Sven A. Wehrwein28,973 45,000 <1%
  • Ownership guidelines: Non-employee directors must hold >3× annual cash retainer within 3 years; CEO 6× salary; other specified officers ≥1× salary .
  • Hedging/pledging: Prohibited under Insider Trading Policy (no pledging or hedging) .

Governance Assessment

  • Strengths: Independent, long-tenured audit chair with SEC “financial expert” designation; consistent attendance and annual meeting participation, supporting board effectiveness .
  • Alignment: Receives majority of compensation via equity (time-based RS), with ownership guidelines in place and hedging/pledging prohibitions; beneficial ownership and exercisable options provide skin-in-the-game though below 1% of class, typical for directors .
  • Committee signal: Audit chair across increasing meeting cadence (5→6), plus participation on Compliance, Quality & Risk, indicating active oversight of financial controls and enterprise risk (including cybersecurity-related accounting risks) .
  • Conflicts/related party exposure: No Item 404 related party transactions disclosed; Audit Committee charter requires review/approval of related party transactions, mitigating risk .
  • RED FLAGS: None disclosed regarding related-party transactions, hedging/pledging, attendance shortfalls, or option repricing for directors in 2023–2024 .